CKPT Logo

Checkpoint Therapeutics, Inc. (CKPT) 

NASDAQ
Market Cap
$191.09M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
606 of 966
Rank in Industry
332 of 554

Largest Insider Buys in Sector

CKPT Stock Price History Chart

CKPT Stock Performance

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Insider Activity of Checkpoint Therapeutics, Inc.

Over the last 12 months, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $125,606 worth of Checkpoint Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Checkpoint Therapeutics, Inc. have bought $0 and sold $250,177 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $127,000 was made by ROSENWALD LINDSAY A MD (director) on 2019‑11‑20.

List of Insider Buy and Sell Transactions, Checkpoint Therapeutics, Inc.

2024-06-26SaleCEO, President and Director
24,610
0.0674%
$2.05$50,451+17.87%
2024-06-26SaleChief Financial Officer
13,038
0.0359%
$2.06$26,858+17.87%
2024-02-28SaleCEO, President and Director
5,894
0.0247%
$2.06$12,142+5.85%
2024-02-28SaleChief Financial Officer
2,035
0.0086%
$2.07$4,212+5.85%
2024-02-01SaleCEO, President and Director
11,900
0.0552%
$2.01$23,919+6.63%
2024-02-01SaleChief Financial Officer
4,115
0.0185%
$1.95$8,024+6.63%
2023-03-02SaleCEO, President and Director
5,483
<0.0001%
$5.00$27,415-55.93%
2023-03-02SaleChief Financial Officer
3,591
<0.0001%
$5.00$17,955-55.93%
2023-02-27SaleCEO, President and Director
5,548
<0.0001%
$4.65$25,798-51.41%
2023-02-27SaleChief Financial Officer
1,914
<0.0001%
$4.66$8,919-51.41%
2023-02-01SaleCEO, President and Director
10,261
<0.0001%
$4.77$48,945-50.47%
2023-02-01SaleChief Financial Officer
3,154
<0.0001%
$4.79$15,108-50.47%
2023-01-10SaleCEO, President and Director
3,817
<0.0001%
$6.75$25,761-62.55%
2023-01-10SaleChief Financial Officer
1,858
<0.0001%
$6.75$12,540-62.55%
2022-06-17SaleCEO, President and Director
15,000
0.0183%
$1.11$16,650-44.09%
2022-04-13SaleCEO, President and Director
21,258
0.024%
$1.51$32,100-35.33%
2022-04-05SaleCEO, President and Director
14,030
0.0164%
$1.77$24,833-42.20%
2022-04-04SaleCEO, President and Director
86,353
0.0998%
$1.79$154,572-42.94%
2022-03-10SaleChief Financial Officer
38,197
0.0447%
$1.89$72,307-43.68%
2022-02-01SaleChief Financial Officer
37,063
0.0429%
$2.51$92,954-55.69%

Insider Historical Profitability

32.45%
Oliviero James F IIICEO, President and Director
1977170
4.1078%
$3.97013
GRAY WILLIAM GARRETTChief Financial Officer
672186
1.3965%
$3.97012
ROSENWALD LINDSAY A MDdirector
237890
0.4942%
$3.9740+32.45%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Armistice Capital Llc$5.57M7.362.72M+11.95%+$594,500.000.02
The Vanguard Group$1.88M2.49917,894+67.41%+$757,651.42<0.0001
Renaissance Technologies$556,000.000.74271,217+63.65%+$216,248.30<0.01
Geode Capital Management$407,028.000.54198,501+14.18%+$50,559.39<0.0001
BlackRock$339,160.000.45165,444-0.64%-$2,197.60<0.0001
Advisor Group Holdings Inc$277,112.000.37135,177-17.21%-$57,617.12<0.01
D. E. Shaw & Co.$222,655.000.29108,612-22.72%-$65,464.82<0.0001
Legacy Wealth Asset Management Llc$174,250.000.2385,0000%+$00.05
Envestnet Asset Management Inc$157,116.000.2176,642+77.49%+$68,597.06<0.0001
Millennium Management LLC$130,038.000.1763,433+432.11%+$105,599.88<0.0001
State Street$124,074.000.1660,5240%+$0<0.0001
Royal Bank of Canada$125,000.000.1660,476-0.31%-$390.65<0.0001
Park Avenue Securities Llc$123,000.000.1659,915-0.03%-$34.90<0.01
Rsm Us Wealth Management Llc$118,740.000.1657,922+200.89%+$79,277.53<0.01
Susquehanna International Group$115,671.000.1556,425-40.64%-$79,205.68<0.0001
Wealth Enhancement Advisory Services LLC$102,500.000.1450,000-41.18%-$71,750.00<0.0001
National Asset Management Inc$83,555.000.1349,150-69.91%-$194,140.00<0.01
Northern Trust$88,863.000.1243,348+9.34%+$7,593.17<0.0001
Lindbrook Capital LLC$61,500.000.0830,000New+$61,500.000.01
Magnus Financial Group LLC$61,500.000.0830,000+25%+$12,300.000.01
CETERA INVESTMENT ADVISERS LLC$49,932.000.0724,357+69.77%+$20,520.56<0.0001
Emfo Llc$32,216.000.0415,7150%+$00.03
Ironwood Investment Management Llc$26,012.000.0312,689+8.61%+$2,062.260.01
Cetera Advisors LLC$25,350.000.0312,366New+$25,350.00<0.0001
Apollon Wealth Management, LLC$23,645.000.0311,534New+$23,645.00<0.01
Cibc Asset Management Inc$23,134.000.0311,2850%+$0<0.0001
Morgan Stanley$21,853.000.0310,659+31.61%+$5,248.49<0.0001
Raymond James Financial Services Advisors Inc$21,720.000.0310,595New+$21,720.00<0.0001
Tower Research Capital$14,813.000.027,226-35.33%-$8,093.24<0.0001
Citadel Advisors LLC$13,719.000.026,692New+$13,719.00<0.0001
Wells Fargo$6,476.000.013,159-81.57%-$28,657.17<0.0001
UBS$3,077.00<0.011,501-1.51%-$47.15<0.0001
Householder Group Estate Retirement Specialist Llc$410.00<0.01200-33.33%-$205.00<0.0001
Tsfg Llc$1,000.00<0.013000%+$0<0.0001
JPMorgan Chase$2.00<0.0110%+$0<0.0001
VisionPoint Advisory Group$205.00<0.01100New+$205.00<0.0001
Fidelity Investments$308.00<0.01150New+$308.00<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.